The Pharmacy and Therapeutics (P&T) Committee
The P&T Committee provides recommendations for the Medicaid Preferred Drug List (PDL). The Committee is composed of Physicians & Pharmacists who meet at least quarterly to consider PDL implementation. These meetings are generally scheduled on the third Thursday of every month at 7:00 A.M. in the Cannon Health Building at 288 N. 1460 W. in Salt Lake City, UT. The P&T Committee reserves the right to adjust the meeting schedule as necessary. Notices for exact meeting times and locations will be published in the Legal Notices sections of the Salt Lake Newspapers at least 24 hours in advance. You may also sign up to receive public notice for this meeting by email.
Public Comments for the P&T Committee:
The meetings are open to the public.
Manufacturers are requested to submit any additional materials they would like reviewed as part of the process to:
Gary M. Oderda, Pharm.D., M.P.H
Professor and Director
Pharmacotherapy Outcomes Research Center
University of Utah College of Pharmacy
421 Wakara Way Suite 208
Salt Lake City, UT 84108
All materials must be clearly labeled that they are submitted for consideration as part of the State of Utah Medicaid Preferred Drug List Program review process. Materials must be received at least 60 days before the scheduled review date. Materials most useful to support the evidence-based process include any new evidence (information from clinical trials or studies when possible) after the Oregon monograph was prepared, unpublished materials the company would like considered as part of the process, or any other materials not likely to be included in a literature search.
Persons who wish to address the P&T Committee may contact Lisa Hunt by phone at 801-538-6317 or by emailat least 7 calendar days prior to the meeting. Comments from visitors, while welcome, may be limited due to time constraints
Listed below is a P&T Committee class review tentative schedule:
Listed below are meeting minutes, agendas, criteria review documents, and reports regarding the P&T Committee. Clinical evidence documents prepared for the P&T Committee meetings will be kept on this website for 6 months.
May 2013: Factor Xa Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist
June 2013: Cancelled due to bid review
July 2013: Sulfonylurea Drug Class Review, Sulfonylurea Combination Products
August2013: Thiazolidinedione Drug Class Review, Thiazolidindione Combination Products Drug Class Review
September 2013: Phosphate Binding Agents Drug Class Review
October 2013: Topical Immune-modulators Drug Class Review
November 2013: Topical/Local Anesthetic Agents Drug Class Review
December 2013: Pediculoside Agents Drug Class Review
January 2014: Long Acting Opioid Agents Drug Class Review
February 2014: Short Acting Opioid Agents Drug Class Review
March 2014: Immediate Acting Opioid Agents Drug Class Review
Search the following files. Note that '*' and '?' wildcards are supported.
| Name | Type | Last Modified |
| Non-Preferred_Drug_Auth.pdf | February 15, 2012 | |
| Minutes | Folder | March 21, 2013 |
| Draft Future Agendas | Folder | April 22, 2013 |
| Criteria Review Documents | Folder | March 21, 2013 |